Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.
Share: email Subscribe
Weekly Top Stories Tue, 27 Jun 2023
We have 30 articles this week,# Quest Diagnostics Completes Acquisition of #Haystack Oncology #Tourmaline Bio, #Talaris Therapeutics Announce Reverse Merger in Stock Deal. #Bio-Techne to Acquire Lunaphore. #Solve Therapeutics, Inc. Acquires Cereius, Inc., a Duke University Spin-Out.#Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics.#. Thermo Fisher Scientific Completes Acquisition of MarqMetrix. #Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash .#DUOS Raises $10M to Empower Older Adults to Live Independently
Editor's Choice
1. 
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
2. 
Rimidi Enhances Integration with Dexcom, Adds Glycemic Risk Index to Diabetes Platform
3. 
States Back FTC in Lawsuit Seeking to Block Amgen-Horizon Deal
4. 
Medtronic, Allurion Launches AI-Powered Weight Loss Piloty
5. 
Key Takeaways from PegaWorld iNspire 2023.
6. 
Outbound AI Raises $16M for AI-Powered Virtual Agents
Top 9 M&A Transactions
7. 
Quest Diagnostics Completes Acquisition of Haystack Oncology
8. 
Tourmaline Bio, Talaris Therapeutics Announce Reverse Merger in Stock Deal
9. 
Bio-Techne to Acquire Lunaphore
10. 
Solve Therapeutics, Inc. Acquires Cereius, Inc., a Duke University Spin-Out
11. 
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics.
12. 
Thermo Fisher Scientific Completes Acquisition of MarqMetrix
13. 
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
14. 
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
15. 
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
Top 4 Venture Funding
16. 
Conformis Announces Definitive Agreement to be Acquired by Restor3d for a Purchase Price of $2.27 Per Share in Cash
17. 
DUOS Raises $10M to Empower Older Adults to Live Independently
18. 
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
19. 
AccurKardia Secures $2.7M for Clinical Grade ECG Analytics
Top 3 Partnerships Announcements
20. 
RLI Transportation Announces Partnership with Fleet Management Firm Motive.
21. 
Integral Ad Science and Meta Expand Partnership for Facebook and Insta reels
22. 
Loop Media, Orange Door Expand Content Partnership in Australia and New Zealand
Read More Corporate Development and M&A Activity
Get Featured: Send us your article or blog and we will feature it on our publication, reach over thousands of executives. Click Here.
Editor: Ed Francis

Ed has more than 25 years of management consulting experience and currently is the Global Managing Partner for Infosys Consulting Health and Life Sciences business guiding some of the industry's most prominent health and life sciences organizations through complex transformations.

If you need help with your complex transformation whether it be M&A, digital, or strategic cost reduction or need to bring more innovation into your business strategy Ed can be contacted at Edward.Francis@infosys.com and +1-847-910-6073

Or connect with him at

OTHER ADVISORIES

Health Plan Hospital IT
IT GovHealth
Retail POP Health
Ageing Life Sciences

Advertise with us

We Reach Half Million Decision Makers in:
Healthcare · IT · Retail · Industrial
Advertise with us and reach the right audience.
advertise@distilnfo.com

Contact Us

5760 Legacy Dr, B3-405,
Plano TX 75024
+1 469-270-3311

DistilINFO Publications

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you - saving time and keeping you up to date on your interest areas.

You are receiving this newsletter because you are subscribed to one or more DistilINFO Publications Newsletter/s. If you feel this email was sent by mistake or you want to opt out, you can unsubscribe.

View in browser | Advertise | Contact Us